Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM). We report results of an early access protocol (EAP) of daratumumab monotherapy for RRMM in a cohort of Brazilian patients. Methods:...

Full description

Bibliographic Details
Main Authors: Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Hematology, Transfusion and Cell Therapy
Subjects:
Daratumumab
Monoclonal antibody
Multiple myeloma
Early access protocol
Brazil
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137920301231

Internet

http://www.sciencedirect.com/science/article/pii/S2531137920301231

Similar Items